1
|
ELBassiouny M. Case report: Long-term survival in a patient with metastatic colorectal cancer treated with trifluridine/tipiracil in the third-line setting. Front Oncol 2023; 13:1112224. [PMID: 36937418 PMCID: PMC10019825 DOI: 10.3389/fonc.2023.1112224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 02/13/2023] [Indexed: 03/06/2023] Open
Abstract
Third-line treatment with trifluridine/tipiracil (FTD/TPI) is recommended for patients with metastatic colorectal cancer (mCRC) or gastric/gastroesophageal cancer (GC) who have progressed beyond first- and second-line therapy. We describe a patient with long-term survival following treatment with FTD/TPI. The patient, a 70-year-old woman diagnosed with right-sided mCRC (T3/N1) with metastases to the aortocaval and precaval lymph nodes, received first-line panitumumab and capecitabine for 6 months, followed by second-line bevacizumab and oxaliplatin. She had disease progression following 9 months of second-line therapy and began third-line treatment with FTD/TPI (50 mg bid). Three months after treatment initiation, lymph node involvement was reduced, and following 12 months of FTD/TPI treatment, her disease had stabilized, and she reported no treatment-related adverse events. She remained on the same dose of FTD/TPI for more than 27 months after initiating treatment, with maintenance of stable disease. This patient with mCRC demonstrated a survival benefit with FTD/TPI beyond those reported in published clinical trial data and real-world studies.
Collapse
|
2
|
Özet A, Dane F, Aykan NF, Yalçın Ş, Evrensel T, Özkan M, Karabulut B, Ormeci MN, Atasev O, Vidot L, Çiçin İ. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey. Future Oncol 2022; 18:3267-3276. [PMID: 36040321 DOI: 10.2217/fon-2022-0455] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Background: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with ≥2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting. Clinical Trial Registration: NCT03306394 (ClinicalTrials.gov).
Collapse
Affiliation(s)
- Ahmet Özet
- Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, 06560, Turkey
| | - Faysal Dane
- Division of Medical Oncology, Department of Internal Medicine, Marmara University Medical Faculty, Istanbul, 34854, Turkey
| | - Nuri Faruk Aykan
- Department of Medical Oncology, Istinye University Medical Faculty, Istanbul, 34010, Turkey
| | - Şuayib Yalçın
- Hacettepe University Institute of Cancer, Department of Medical Oncology, Ankara, 06230, Turkey
| | - Türkkan Evrensel
- Department of Medical Oncology, Uludağ University Medical Faculty, Bursa, 16059, Turkey
| | - Metin Özkan
- Department of Medical Oncology, Erciyes University Medical Faculty, Kayseri, 38280, Turkey
| | - Bülent Karabulut
- Department of Medical Oncology, Özel İzmir Kent Hospital, İzmir, 35620, Turkey
| | | | - Ozan Atasev
- Servier Pharmaceuticals, Istanbul, 34398, Turkey
| | - Loïck Vidot
- Servier Pharmaceuticals, Suresnes, 92150, France
| | - İrfan Çiçin
- Department of Medical Oncology, Trakya University, Edirne, 22030, Turkey
| |
Collapse
|
3
|
Zhang Q, Wang Z, Zhang Z, Zhu L, Yang X. Analysis of microarray-identified genes and MicroRNAs associated with Trifluridine resistance in colorectal cancer. ALL LIFE 2022. [DOI: 10.1080/26895293.2022.2080280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Affiliation(s)
- Qiqi Zhang
- Department of Integrated Chinese and Western Medicine, Zhongshan Hospital Affiliated to Fudan University, Shanghai, People’s Republic of China
| | - Zhan Wang
- Department of Medical Oncology, Changzheng Hospital, Second Military Medical University, Shanghai, People’s Republic of China
| | - Zhenghua Zhang
- Department of Clinical Oncology, Jing’An District Centre Hospital of Shanghai, Huashan Hospital Fudan University Jing’An Branch, Shanghai, People’s Republic of China
| | - Lifei Zhu
- Cancer Center, Shanghai Jiaotong University Affiliated First People’s Hospital, Shanghai, People’s Republic of China
| | - Xijing Yang
- Department of Biotherapy, The Eastern Hepatobiliary Surgery Hospital, Naval Military Medical University, Shanghai, People’s Republic of China
| |
Collapse
|